EMPLOYMENT AGREEMENTEmployment Agreement • March 12th, 2019 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
THIS EMPLOYMENT AGREEMENT (the “Agreement”), is made as of March 21, 2018 among Nabriva Therapeutics US, Inc. (the “Company”), Nabriva Therapeutics plc and Jennifer Schranz (the “Executive”) (together, the “Parties”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. API SUPPLY AGREEMENTApi Supply Agreement • March 12th, 2019 • Nabriva Therapeutics PLC • Pharmaceutical preparations • England and Wales
THIS ACTIVE PHARMACEUTICAL INGREDIENT SUPPLY AGREEMENT (this “Agreement”) is made as of this 23rd day of November 2018 (“Effective Date”), by and between NABRIVA THERAPEUTICS IRELAND DAC (“NABRIVA”), with a principal place of business at Suite 510, Regus Dublin Airport, Skybridge House Dublin Airport, Swords, County Dublin, Ireland and HOVIONE LIMITED (“HOVIONE”), with a principal place of business at Loughbeg, Ringaskiddy, Co. Cork, Ireland. NABRIVA and HOVIONE shall be individually referred to as a “Party” and collectively referred to as the “Parties.”
AGREEMENT FOR THE COMMERCIAL & SUPPLY OF PRODUCTSAgreement for the Commercial & Supply of Products • March 12th, 2019 • Nabriva Therapeutics PLC • Pharmaceutical preparations
THIS AGREEMENT (the “Agreement”) is made on the 12th day of November, 2018 between ARRAN CHEMICAL COMPANY LIMITED, of Units 1-3 Monksland Industrial Estate, Athlone, Republic of Ireland (hereinafter referred to as “ARRAN”); and NABRIVA THERAPEUTICS IRELAND DAC, of Suite 510, Regus Dublin Airport, Skybridge House Dublin Airport, Swords, County Dublin, Ireland (“CLIENT”)
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 12th, 2019 • Nabriva Therapeutics PLC • Pharmaceutical preparations • New York
THIS LOAN AND SECURITY AGREEMENT is made and dated as of December 20, 2018 and is entered into by and among Nabriva Therapeutics Public Limited Company, a public limited company incorporated in Ireland under registration number 599588 and having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (“Parent”), Nabriva Therapeutics Ireland Designated Activity Company, a designated activity company incorporated in Ireland under registration number 612454 and having its registered office at Suite 510, Regus Dublin Airport, Skybridge House, Dublin Airport, Swords, County Dublin, Ireland (“Nabriva Ireland”; together with Parent, individually and collectively, jointly and severally, the “Borrower”), Nabriva Therapeutics GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated under the laws of the Republic of Austria, having its seat in Vienna and its registered address at Leberstraße 20, 1110 Vienna, and registered with the companies’ register (Firm
